FDA Mission Includes Clearer Efficacy Guidance – Vanderbilt’s Wood
This article was originally published in The Tan Sheet
Executive Summary
FDA's focus on post-marketing safety should be accompanied by clearer clinical efficacy standards, Vanderbilt Assistant Vice Chancellor Alastair Wood, MD, suggested during a March 6 hearing on user fees
You may also be interested in...
Bush Seeking New FDA Commissioner Candidates With Wood Cut From List
The Bush Administration once again is seeking names of potential FDA commissioner candidates
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands